TALWIN SOLUTION

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

PENTAZOCINE (PENTAZOCINE LACTATE)

MAH:

PFIZER CANADA ULC

ATC_code:

N02AD01

INN:

PENTAZOCINE

dosage:

30MG

pharmaceutical_form:

SOLUTION

composition:

PENTAZOCINE (PENTAZOCINE LACTATE) 30MG

administration_route:

INTRAMUSCULAR

units_in_package:

1ML

prescription_type:

Narcotic (CDSA I)

therapeutic_area:

OPIATE PARTIAL AGONISTS

leaflet_short:

Active ingredient group (AIG) number: 0108852001; AHFS:

authorization_status:

CANCELLED POST MARKET

authorization_date:

2019-11-21

SPC

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
TALWIN
(Pentazocine Lactate Injection, USP)
30 mg/mL
Sterile Solution
Narcotic Analgesic
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Submission Control No.: 213124
Date of Revision:
April 17, 2018
_Product Monograph _
_N_
_Talwin _
_Page 2 of 30 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
................................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
PATIENT MEDICATION INFORMATION
...............................